AURA insider files Form 144 for 1,581 shares

Amy Elazzouzi reported a sale of 1,581 shares of Common Stock on 01/20/2026.

Rhea-AI Filing Summary

Amy Elazzouzi reported a sale of 1,581 shares of Common Stock on 01/20/2026. The filing shows Restricted Stock Unit awards of 4,583 granted 02/01/2024 and 11,310 granted 02/03/2025, each described as subject to vesting under the 2021 Stock Option and Incentive Plan.

The broker listed is Morgan Stanley Smith Barney LLC at the address shown, and the filing references Nasdaq with an apparent filing activity date of 02/17/2026.

Insights

Securities Compliance Analyst

Form 144 discloses an affiliated sale of 1,581 shares and two RSU grants tied to vesting schedules.

The filing lists a sale by Amy Elazzouzi of 1,581 shares on 01/20/2026. It also records two Restricted Stock Unit awards: 4,583 (granted 02/01/2024) and 11,310 (granted 02/03/2025), each described as subject to vesting under the 2021 Stock Option and Incentive Plan.

Cash‑flow treatment and whether the RSUs are vested at sale are not stated in the excerpt; subsequent filings or company disclosures may clarify timing and proceeds. The broker shown is Morgan Stanley Smith Barney LLC.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Form 144 for AURA report?

The Form 144 reports a sale of 1,581 common shares by Amy Elazzouzi on 01/20/2026. It also lists RSU grants of 4,583 (02/01/2024) and 11,310 (02/03/2025) subject to vesting.

Who is the broker listed on the AURA Form 144?

The filing lists Morgan Stanley Smith Barney LLC with the address shown in the excerpt. The broker is identified in the securities reporting section associated with the sale transaction.

Do the RSU grants on the filing mean those shares were sold?

No; the RSU entries are described as restricted stock unit awards subject to vesting under the 2021 plan. The filing separately shows the actual sale quantity of 1,581 shares on 01/20/2026.

When were the RSU awards granted according to the filing?

The excerpt shows RSU grants dated 02/01/2024 for 4,583 units and 02/03/2025 for 11,310 units, each noted as subject to vesting requirements under the issuer's plan.

Does the Form 144 state proceeds or who received sale proceeds?

The provided excerpt does not state where sale proceeds were directed. The filing lists the sale quantity and broker, but cash‑flow treatment is not disclosed in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 07:50 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002042910
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Aura Biosciences, Inc.
SEC File Number	001-40971
Address of Issuer	80 Guest Street Boston MASSACHUSETTS 02135
Phone	617-500-8864
Name of Person for Whose Account the Securities are To Be Sold	Elazzouzi Amy
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Drive 200 West Civic Center 4th Floor Sandy UT 84070	8549	43260.99	63503269	02/17/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/01/2024	Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.	Aura Biosciences, Inc.			4583	02/01/2024	N/A
Common Stock	02/03/2025	Restricted Stock unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, subject to vesting requirements.	Aura Biosciences, Inc.			11310	02/03/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Amy Elazzouzi 80 Guest Street Boston MA 02135	Common Stock	01/20/2026	1581	7683.66

144: Remarks and Signature

Remarks	The sales reported on this Form 144 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
Date of Notice	02/17/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Amy Elazzouzi
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)